RPL36 was reported as a tumor suppressor to restrain KRAS-induced pancreatic cancer (Provost et al., 2014), and was a promising prognostic marker in hepatocellular carcinoma (Song et al., 2011). This evidence concerns the gene KRAS and pancreatic neoplasm.